Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitors

7 May 2015

Abstract excerpt

// Audrey Delmas 1, 2, 3 , Julia Cherier 1, 3 , Magdalena Pohorecka 1, 2, 3 , Claire Medale-Giamarchi 1, 2, 3 , Nicolas Meyer 1, 2, 4 , Anne Casanova 3 , Olivier Sordet 1, 3 , Laurence Lamant 1, 5 , Ariel Savina 6 , Anne Pradines 1, 2, 3 , Gilles Favre 1, 2, 3 1 Inserm, UMR 1037-CRCT, Toulouse, France 2 Université Paul Sabatier, Toulouse, France 3 Institut Claudius Regaud, Institut Universitaire du Cancer de...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26098773
DOI: 10.18632/oncotarget.3888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitorsPMID 26098773Read ↗

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseSemantic proximity Read ↗

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read ↗

A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibitionSemantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

BRAF inhibitors: resistance and the promise of combination treatments for melanomaSemantic proximity Read ↗

B-RAF: A contributor to the melanoma phenotype.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: Implications for the involvement of pirinSemantic proximity Read ↗

Overcoming resistance to BRAF inhibitorsSemantic proximity Read ↗

Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.Semantic proximity Read ↗

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in MelanomaSemantic proximity Read ↗

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.